Susan B. Hirsch, a director at TECOGEN INC (NASDAQ:TGEN), completed a purchase of 10,000 common shares on March 27, 2026. The shares were acquired at $2.54 apiece for a total outlay of $25,400.
Following this transaction, Hirsch directly holds 260,416 shares of Tecogen. At the time the purchase was reported, the stock was trading at $2.57, representing a roughly 17% gain for the share price over the prior week.
Third-party research cited in market commentary indicates that TGEN appears undervalued at current levels according to InvestingPro analysis. An InvestingPro note included with that assessment highlights that Tecogen’s balance sheet includes more cash than debt. The same service advertises access to 10 additional ProTips and a full Pro Research Report for investors seeking deeper analysis.
Those market-level observations arrive alongside the company’s published fourth-quarter 2025 results, which fell short of expectations. Tecogen reported an earnings per share (EPS) of -$0.13, below the consensus forecast of -$0.04, a negative surprise quantified at 225%. Quarterly revenue was $5.3 million, missing the projected $7.27 million and representing a 26.82% shortfall versus the revenue estimate.
These reported results have prompted concern among investors about the company’s near-term financial performance. The combination of an insider purchase, recent shortfall in quarterly results, and external commentary on valuation and balance-sheet composition presents a mixed picture for market participants monitoring TGEN.
For investors interested in additional research, the InvestingPro references indicate further proprietary tips and a Pro Research Report are available through that service.
Summary
A director at Tecogen purchased 10,000 shares on March 27, 2026 at $2.54 each, bringing her direct holdings to 260,416 shares. The trade occurred while the stock traded at $2.57 after a recent 17% weekly rise. InvestingPro analysis characterizes the stock as undervalued and notes Tecogen holds more cash than debt. Separately, Tecogen’s Q4 2025 results missed expectations on both EPS and revenue, raising investor concerns.